arrow
D

Denarda Dangaj Laniti

university of lausanne
H指数:26
被引数:4,169

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Rethinking ovarian cancer III: the past decade and future directions

重新思考卵巢癌III:过去十年及未来方向

2026-04-130
PRE
Highly efficient gene knockout in tumor-infiltrating lymphocytes by adenine base editing

腺嘌呤碱基编辑介导的肿瘤浸润淋巴细胞高效基因敲除

2025-09-010
OAAI
Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer

髓系细胞网络调控复发性卵巢癌中原有免疫景观的重新建立

2025-07-310
OAAI
Cancer cells impair monocyte-mediated T cell stimulation to evade immunity

癌细胞损害单核细胞介导的T细胞刺激以逃避免疫

Nature
IF48.5
2024-11-270
OAAI
A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy

用于新抗原发现的全面蛋白质基因组学流程,以推进个性化癌症免疫疗法

2024-10-111
OAAI
Predicting Antigen-Specificities of Orphan T Cell Receptors from Cancer Patients with TCRpcDist

预测患有TCRpcDist的癌症患者的孤儿T细胞受体的抗原特异性

2024-08-190
OAAI
Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithms (May, 10.1038/s41587-024-02318-9, 2024)
2024-06-250
OAAI
Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithms

使用组合算法鉴定个性化T细胞治疗的临床相关T细胞受体

2024-05-074
OAAI
PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells

PGE2限制肿瘤浸润性干细胞样CD8 T细胞的效应子扩增

Nature
IF48.5
2024-04-240
OAAI
Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8+ T-myeloid cell networks in melanoma

对肿瘤浸润淋巴细胞过继治疗的反应与黑色素瘤中预先存在的CD8 T髓样细胞网络有关

2024-02-0216
OA
PGE2 inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function

PGE2通过破坏IL-2信号和线粒体功能抑制TIL扩增

Nature
IF48.5
2024-01-010
OAAI
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer
2023-09-218
PRE
Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors

具有高结构亲和力的新抗原特异性CD8 T细胞优先驻留并消除肿瘤

2023-06-0627
OAAI
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy

低剂量放射治疗可逆转肿瘤免疫荒漠化和对免疫疗法的抵抗力

2021-09-03215
OAAI
Principal results of the EORTC-1508 trial: A phase II randomised, multicentre study of bevacizumab vs atezolizumab and bevacizumab with acetylsalicylic acid or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma
2021-09-013
OAAI